A Phase 1 Study of ASP1893 in Participants With Metastatic or Locally Advanced CLDN6-positive Solid Tumors
Latest Information Update: 15 Nov 2024
Price :
$35 *
At a glance
- Drugs ASP 1893 (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Testicular cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma Global Development
- 15 Nov 2024 New trial record